virus
modifi
genom
mrna
end
addit
rna
cap
allow
effici
mrna
translat
limit
degrad
cellular
exonucleas
avoid
recognit
foreign
rna
host
cell
viral
rna
cap
synthes
acquir
use
cap
machineri
exhibit
signific
divers
organ
structur
mechan
rel
cellular
host
therefor
viral
rna
cap
emerg
interest
field
antivir
drug
design
review
differ
pathway
mechan
use
produc
viral
mrna
present
current
structur
mechan
inhibitor
known
act
viral
rna
cap
eukaryot
cell
rna
cap
cotranscript
event
consist
chemic
modif
nascent
mrna
end
sinc
earli
virus
play
pivot
role
discoveri
structur
character
rna
cap
fig
well
mechanist
elucid
rna
cap
pathway
incident
viru
famili
discoveri
made
reovirida
poxvirida
use
rna
cap
pathway
turn
eukaryot
host
soon
discoveri
viru
famili
found
deviat
substanti
convent
pathway
see
convent
pathway
cap
structur
ad
nascent
triphosph
mrna
seri
reaction
fig
triphosph
first
hydrolys
rna
triphosphatas
rtpase
guanylyltransferas
gtase
also
call
cap
enzym
add
cap
structur
form
guanosin
monophosph
orient
cap
methyl
onto
posit
guanin
rna
cap
guanin
mtase
gener
minim
found
metazoan
lower
eukaryot
higher
eukaryot
methyl
ribos
omethyltransferas
mtase
occur
posit
ribos
origin
transcript
yield
mainli
also
structur
presenc
cap
ensur
stabil
transcript
varieti
cellular
exonucleas
recognit
mrna
ribosom
protein
effici
translat
cap
also
shown
involv
cellular
process
rna
splice
export
darnel
filipowicz
et
al
schibler
perri
coupl
rna
transcript
rna
cap
mainli
nuclear
process
although
rna
recap
event
suspect
occur
cytoplasm
review
schoenberg
maquat
virus
gener
replic
cytoplasm
caus
timewindow
viral
rna
synthes
yet
cap
viru
cell
coevolut
gener
number
cellular
pathway
protein
involv
sens
presenc
viral
rna
absenc
rna
cap
well
presenc
doubl
strand
rna
strong
token
viral
infect
rna
speci
alon
togeth
detect
nonself
rna
cellular
sensor
trigger
innat
cellular
immun
respons
koyama
et
al
takeuchi
akira
wilkin
gale
virus
evolv
numer
strategi
escap
detect
includ
rapid
effici
viral
rna
cap
viru
famili
genera
reli
rna
cap
picornavirida
use
protein
rna
synthesi
primer
protein
replac
rna
cap
role
transcript
promot
rna
protect
virus
pestiviru
hepaciviru
genera
use
unprotect
triphosph
rna
end
strategi
defend
rna
cell
immun
system
garaigorta
chisari
guidotti
chisari
malmgaard
howev
vast
major
virus
use
rna
cap
ongo
deciph
viral
rna
cap
machineri
true
divers
mechan
partner
pathway
organ
invari
lead
rna
structur
progress
uncov
divers
differ
cellular
rna
cap
machineri
draw
lot
attent
antivir
drug
design
factor
bear
mind
consid
rna
cap
interest
drug
design
target
specif
often
put
forward
requir
uniqu
viral
target
ie
nonexist
similar
cellular
target
could
also
hit
antivir
drug
caus
seriou
sideeffect
interestingli
even
viral
enzym
remain
close
structur
mechan
cellular
counterpart
remain
structur
function
differ
potenti
use
achiev
differenti
inhibit
ie
select
viral
target
case
viral
enzym
profoundli
origin
fold
organ
mechan
provid
larg
chemic
space
drug
design
drug
select
potenc
anoth
import
paramet
expect
outcom
viral
target
inhibit
question
whether
vitro
inhibit
effect
lead
signific
block
viral
growth
must
answer
one
consid
two
major
mechan
action
viral
target
enzym
inhibit
enzym
fig
rna
cap
structur
cap
consist
blue
box
link
nucleosid
messeng
rna
chain
triphosph
bridg
pink
box
methyl
group
guanosin
posit
surround
green
methyl
group
first
second
nucleotid
residu
form
structur
respect
surround
light
orang
activ
may
exponenti
consequ
hand
viru
may
develop
altern
pathway
order
resist
antivir
molecul
exampl
flaviviru
cap
inhibitor
valid
sinc
dengu
viru
also
shown
perform
capindepend
translat
rna
genom
edgil
et
al
anoth
possibl
target
protein
bind
partner
devoid
catalyt
activ
part
proteinprotein
bind
equilibrium
inhibit
would
shift
equilibrium
accord
law
mass
action
protein
dosag
must
fine
tune
exert
power
antivir
effect
case
signific
effect
viral
growth
must
observ
valid
target
appropri
amplifi
mechan
lastli
one
consid
number
event
protein
target
involv
viru
lifecycl
exampl
rnadepend
rna
polymeras
rdrp
incorpor
sever
thousand
nucleotid
produc
singl
rna
genom
inhibit
viral
rdrp
nucleotid
incorpor
exhibit
power
antivir
effect
contrast
rna
cap
event
vari
singl
cap
event
eg
genom
ss
rna
virus
mani
rna
cap
event
eg
nidoviral
mononegaviral
etc
nevertheless
connect
rna
cap
antivir
innat
immun
pathway
expect
amplifi
drug
action
rna
cap
immatur
incomplet
rna
cap
may
exhibit
alter
express
profil
may
also
detect
varieti
innat
immun
sensor
add
anoth
direct
neg
effect
viral
growth
context
noteworthi
efficaci
rna
cap
inhibit
demonstr
inhibit
flaviviru
mtase
catalyz
two
methyl
per
synthesi
entir
rna
genom
report
abl
complet
suppress
viral
replic
dong
et
al
alongsid
discoveri
convent
cellular
viral
rna
cap
fig
virus
provid
remark
except
seemingli
ubiquit
presenc
cap
mrna
eukarya
mention
picorna
hepaciand
pestivirus
soon
discov
virus
also
use
unconvent
rna
cap
reaction
deviat
convent
rna
cap
scheme
exampl
fig
complet
review
decroli
et
al
nevertheless
truli
remark
sever
wide
differ
rna
cap
reaction
pathway
converg
rna
cap
structur
fig
observ
indic
evolutionari
pressur
keep
structur
protect
rna
must
signific
viral
rna
cap
thu
interest
target
drug
design
follow
section
summar
current
knowledg
viral
enzym
involv
convent
unconvent
rna
cap
main
refer
structur
fig
report
inhibitor
fig
capsnatch
mechan
endonucleas
captur
cellular
mrna
cell
blue
snatch
cleav
transfer
cap
structur
follow
seven
eleven
base
polymeras
start
viral
mrna
green
residu
cellular
rna
serv
decoy
innat
immun
rna
cap
viral
enzym
undistinguish
cellular
mrna
thu
translat
protein
hostcel
ribosom
machineri
schemat
list
exampl
virus
acquir
cap
structur
use
cap
snatch
mechan
triphosphoryl
mrna
enzym
conserv
amongst
differ
kingdom
life
mean
activ
found
within
domain
singl
protein
present
structur
mechanist
divers
detail
review
decroli
et
al
these
divers
make
rtpase
attract
target
develop
specif
select
inhibitor
rtpase
inde
separ
two
class
sort
mechanist
criteria
ie
either
metalindepend
depend
mechan
gu
lima
shuman
separ
also
divid
higher
eucaryot
rtpase
includ
human
vast
major
viral
rtpase
metalindepend
rtpase
far
lone
structur
famili
includ
human
rtpase
higher
eukaryot
plant
virus
like
baculoviru
substrat
bind
catalyt
site
enzym
locat
ploop
enrich
histidin
cystein
mediat
twostep
reaction
coval
phosphoenzym
intermedi
changela
et
al
denu
dixon
altern
viral
metaldepend
rtpase
structur
mechanist
varieti
found
year
metaldepend
rtpase
organ
three
superfamili
hitlik
fold
ab
complex
jayaram
et
al
triphosph
tunnel
metalloenzym
ttm
benarroch
et
al
gu
lima
lima
et
al
shuman
viral
rna
helicaselik
fold
carri
one
socal
walker
motif
benarroch
et
al
hitlik
fold
fig
rtpase
iii
found
rotaviru
protein
magnesium
depend
ntpasertpas
hydrolysi
activ
capabl
remov
cphosphat
either
ntp
rna
jayaram
et
al
activ
share
catalyt
site
mechan
also
switch
one
activ
substrat
depend
ntp
ppprna
protein
selfassembl
doughnutshap
octam
bind
singlestrand
rna
destabil
rnarna
duplex
monom
two
subdomain
separ
deep
electroposit
cleft
contain
histidin
residu
involv
bind
hydrolysi
ntp
well
rna
vasquezdel
carpio
et
al
cleft
orient
surfac
doughnut
ntermin
subdomain
mostli
ahel
ctermin
domain
adopt
ab
fold
central
twist
antiparallel
bsheet
made
bstrand
flank
ahelic
protein
structur
compon
rna
packag
part
cap
machineri
due
uniqu
structur
featur
consid
target
choic
develop
antivir
compound
enzym
ttm
superfamili
hydrolyz
ntp
ndp
pi
presenc
manganes
cobalt
found
fungi
protozoa
dna
virus
encod
rtpase
orthopoxviru
chloroviru
baculovirida
mimiviru
rtpase
saccharomyc
cerevisia
serv
model
fig
rtpase
present
structur
tunnel
compos
eight
antiparallel
b
strand
motif
encompass
two
glutam
lehman
et
al
lima
et
al
tunnel
harbor
sever
charg
hydrophil
side
chain
coordin
manganes
sulfat
ion
sulfat
thought
indic
posit
cphosphat
newli
synthes
mrna
dockingmodelingbas
studi
seri
nucleosid
analogu
triphosph
triphosph
triphosph
identifi
high
affin
bind
resist
hydrolysi
despin
et
al
issur
et
al
last
identifi
superfamili
viral
rna
helicaselik
fold
fig
rtpase
ii
carri
ntpasehelicas
activ
rtpase
found
rna
viru
genera
famili
flaviviru
coronavirida
orthoreoviru
alphaviru
potexviru
structur
belong
either
helicas
superfamili
viral
helicas
crystal
structur
belong
superfamili
determin
date
yet
fold
thought
diverg
canon
cordin
et
al
hand
fold
form
two
recalik
subdo
main
separ
cleft
accommod
either
nucleotid
triphosph
rna
substrat
two
subdomain
carri
walker
motif
motif
form
ploop
stabil
termin
phosphat
moieti
substrat
b
motif
compos
acid
residu
dexd
coordin
dival
ion
need
substrat
hydrolysi
catalyt
site
describ
cleft
accommod
rna
substrat
nucleotid
could
use
target
drug
design
howev
effort
need
better
understand
fine
mechanist
would
lead
ration
drug
design
amongst
differ
famili
viral
rtpase
inhibit
studi
identifi
potenti
interest
compound
fig
respect
least
neglect
rtpase
dna
paramecium
bursaria
chlorella
viru
surprisingli
phosphat
analogu
see
fig
rtpase
inhibitor
ii
also
vanad
weak
inhibitor
druglik
properti
takagi
et
al
famili
flaviviru
enzym
may
greater
valu
sinc
addit
rtpase
activ
habour
two
activ
helicas
ntpase
rtpase
activ
site
superimpos
ntpase
activ
site
provid
energi
unwind
dsrna
suppress
rtpasentpas
activ
abrog
helicas
activ
therefor
like
bifunct
inhibitor
discov
near
futur
one
exampl
approach
studi
inhibitori
potenti
purin
analogu
one
structur
fig
rtpase
inhibitor
iii
expect
inhibit
three
activ
despin
et
al
gtase
fig
gtase
respons
attach
gmp
molecul
onto
premrna
contrari
rtpase
fold
mechan
seem
well
conserv
amongst
kingdom
life
make
de
facto
gtase
difficult
target
specif
inhibitor
develop
yet
possibl
viral
kingdom
gtase
exhibit
mechan
new
fold
would
make
gtase
good
candid
drug
develop
assumpt
come
difficulti
identifi
gtase
viral
world
presenc
gtase
domain
embed
within
larger
protein
protein
l
mononegaviral
variant
gtase
domain
found
cypoviru
cheng
et
al
fig
gtase
ii
known
gtase
protein
far
adopt
modular
organ
contain
ntermin
nucleotid
transferas
domain
atpgrasp
fold
ctermin
domain
oligonucleotideoligosaccharid
bind
fold
obfold
posit
lid
base
subdomain
ntermin
domain
fig
gtase
gtpbind
site
locat
base
hing
highli
conserv
gtase
dsdna
virus
human
catalyt
site
defin
presenc
six
conserv
motif
motif
contain
lysin
coval
link
gmp
hydrolysi
ppi
gtp
transfer
onto
rna
conserv
motif
form
bind
pocket
nucleotid
gtase
ds
rna
virus
orthoreoviru
genu
form
part
multidomain
protein
assembl
line
carri
rna
cap
function
gtase
domain
probabl
exist
transient
fold
clearli
defin
wherea
methyltransferas
domain
identifi
nevertheless
catalyt
residu
also
conserv
lysin
sutton
et
al
compound
describ
could
provid
use
start
drug
design
case
dna
virus
enzym
share
structur
function
similar
ligas
protein
superfamili
rais
potenti
difficulti
achiev
select
insid
host
cell
pyrophosph
analogu
foscarnet
phosphon
acid
deriv
fig
gtase
inhibitor
shown
inhibit
reaction
surprisingli
sinc
reaction
produc
pyrophosph
et
al
case
sever
viral
famili
gtase
still
unknown
coronavirus
flavivirus
flavivirus
gtase
activ
might
express
ntermin
domain
protein
carri
also
relat
rna
cap
activ
mtase
issur
et
al
therefor
structur
mechanist
studi
may
provid
effici
drug
lead
target
sever
activ
case
ribavirin
guanin
nucleotid
analogu
target
gtase
mtase
benarroch
et
al
bougi
bisaillon
last
step
cap
format
consist
methyl
cap
rna
cap
methyltransferas
fig
mtase
posit
guanin
methyl
mtase
first
nucleotid
rna
transcript
methyl
ribos
oh
posit
mtase
see
fig
sadenosyllmethionin
sam
methyl
donor
methyl
gener
sadenosyllhomocystein
sah
byproduct
two
methyl
either
done
specif
protein
domain
canon
samdepend
mtase
fold
present
altern
b
strand
helic
form
sevenstrand
b
sheet
least
three
parallel
helic
side
ab
fold
structur
reminisc
rossmann
fold
also
found
dinucleotidebind
domain
dinucleotidebind
protein
sambind
region
locat
ntermin
part
b
sheet
form
part
residu
loop
follow
central
strand
sheet
substratebind
region
respons
select
bind
nucleic
acid
locat
ctermin
part
b
sheet
depend
natur
methyl
addit
structur
featur
found
help
accommod
stabil
substrat
mtase
vaccinia
viru
vv
serv
structur
refer
model
mtase
activ
carri
complex
ctermin
domain
protein
protein
domain
present
characterist
core
ab
fold
mtase
famili
fig
mtase
protein
lack
proper
sam
bind
site
show
activ
contrast
stimul
mtase
activ
affect
extent
substrat
bind
catalyt
subunit
rather
alloster
role
increas
affin
ligand
well
increas
overal
stabil
complex
recent
similar
find
shown
sar
mtase
activ
harbor
protein
stimul
small
regulatori
protein
decroli
et
al
egloff
et
al
later
shown
sambind
site
use
mtase
activ
ray
et
al
core
structur
domain
consist
bsheet
surround
four
ahelic
fig
mtase
iii
catalyt
site
identifi
univers
tetrad
kdke
fig
mtase
iii
core
structur
suppos
rearrang
yet
optim
methyl
flaviviru
cap
requir
distinct
biochem
condit
suggest
two
methyl
occur
differ
mechan
mutagenesi
tetrad
shown
kdke
catalyt
tetrad
essenti
methyl
structur
studi
still
investig
determin
complet
catalyt
site
mtase
ray
colleagu
ray
et
al
shown
two
cap
methyl
event
sequenti
reaction
control
steric
constraint
substrat
inde
methyl
requir
wildtyp
nucleotid
g
u
posit
stemloop
structur
whilst
subsequ
methyl
requir
wildtyp
nucleotid
g
posit
minimum
nucleotid
viral
rna
explor
mtase
constitut
activ
grow
field
amongst
viral
rna
cap
target
last
year
seen
viral
rna
cap
mtase
come
increasingli
focu
target
discoveri
develop
antivir
dong
et
al
issur
et
al
liu
et
al
inhibit
mtase
activ
expect
exert
deleteri
effect
viral
replic
block
viral
rna
translat
essenti
viral
replic
clearli
demonstr
sever
viral
famili
almazan
et
al
dong
et
al
ray
et
al
zhou
et
al
contrast
mutat
analysi
indic
mtase
inhibit
weak
effect
viru
replic
cell
cultur
ray
et
al
zhou
et
al
nevertheless
mtase
also
consid
potenti
target
due
demonstr
rna
lack
omethyl
cap
structur
induc
antivir
respons
sensor
et
al
virus
mutat
mtase
gene
accordingli
show
strongli
reduc
replic
capac
anim
model
daffi
et
al
led
reevalu
import
omethyl
review
decroli
et
al
discoveri
inhibitor
viral
mtase
start
elucid
rna
cap
start
dsdna
poxvirida
field
sam
analogu
sinefungin
fig
mtase
inhibitor
report
first
potent
inhibitor
vv
mtase
activ
pugh
et
al
potent
antivir
effect
shown
plaqu
format
assay
anoth
earli
studi
describ
inhibit
mtase
mtase
activ
vv
link
oligo
adenyl
acid
triphosph
sharma
goswami
interestingli
molecul
natur
metabolit
produc
host
cell
part
innat
immun
respons
viral
infect
review
decroli
et
al
later
multi
substrat
adduct
inhibitori
activ
vv
mtase
report
fig
mtase
inhibitor
ii
benghiat
et
al
sah
analogu
shown
inhibit
vv
herp
simplex
viru
hsv
respect
mtase
propos
potenti
molecular
target
balzarini
et
al
concern
rna
viru
mtase
part
convent
cap
machineri
flaviviru
coronaviru
mtase
particularli
explor
dengu
viru
mtase
activ
shown
inhibit
gtpanalogu
ribavirin
triphosph
benarroch
et
al
sinefungin
sah
base
known
complex
structur
dengu
viru
mtase
domain
benarroch
et
al
egloff
et
al
egloff
et
al
defin
rna
cap
bind
site
omethyl
latter
actual
activ
site
well
sambind
site
sever
group
employ
virtual
screen
dock
procedur
identifi
potenti
ligand
thu
inhibitor
lim
et
al
luzhkov
et
al
milani
et
al
podvinec
et
al
molecul
found
present
inhibitori
activ
micromolar
rang
vitro
enzymat
assay
luzhkov
et
al
milani
et
al
podvinec
et
al
see
exampl
fig
mtase
inhibitor
iv
new
conserv
hydrophob
bind
pocket
next
sambind
site
identifi
flaviviru
mtase
critic
viral
replic
cap
methyl
invit
design
sam
analogu
also
interact
adjac
hydrophob
site
thu
potent
specif
comparison
sam
analogu
sinefungin
highthroughput
screen
use
mtase
activ
assay
gtpbind
assay
set
use
identifi
inhibitor
molecul
geiss
et
al
lim
et
al
concern
coronaviru
mtase
search
antivir
less
activ
sam
analogu
test
found
inhibit
mtase
activ
mtase
activ
low
micromolar
rang
one
identifi
molecul
aurintricarboxyl
acid
ata
fig
mtase
inhibitor
iii
also
inhibit
sarscov
replic
infect
cell
et
al
indirect
approach
inhibit
viral
mtase
consid
coronaviru
mtase
activ
depend
interact
protein
decroli
et
al
lugari
et
al
molecul
disrupt
interact
expect
inhibit
mtase
activ
thu
viral
replic
approach
also
consid
mtase
activ
protein
vv
depend
activ
stimulatori
protein
de
la
et
al
capassembl
line
protein
found
sever
dsrna
virus
reovirida
multidomain
function
protein
packag
genom
viral
particl
abl
perform
four
reaction
need
synthes
structur
domain
cap
assembl
line
must
tightli
regul
coordin
accomplish
sequenti
step
cap
synthesi
pathway
exhibit
activ
independ
synergi
cap
process
individu
domain
correspond
gtase
mtase
character
similar
fold
previous
describ
although
unclear
rtpase
activ
occur
complet
pathway
propos
guanylyl
transfer
follow
omethyl
mrna
domainfunct
could
target
individu
entir
protein
also
consid
room
specif
develop
steric
impair
necessari
dynam
movement
respect
domain
far
though
specif
inhibitor
cap
assembl
line
either
associ
enzym
activ
describ
first
indic
exist
deviat
convent
viral
rna
cap
pathway
came
earli
around
time
discoveri
rna
cap
structur
sinc
demonstr
vesicular
stomat
viru
vsv
mononegaviral
alphavirus
togavirida
synthes
viral
rna
cap
ident
cellular
rna
cap
albeit
two
complet
differ
mechan
togavirida
proceed
synthes
structur
remain
interest
enigma
sinc
mani
member
famili
product
infect
insect
mammal
mononegaviral
order
also
refer
negativestrand
nonseg
nn
rna
virus
compris
major
human
pathogen
rabi
viru
rhabdovirida
measl
viru
paramyxovirina
bornaviru
bornavirida
ebolamarburg
virus
filovirida
rna
cap
achiev
multifunct
l
protein
carri
rnadepend
rna
polymeras
rdrp
rna
cap
synthesi
activ
shortli
discoveri
rna
cap
convent
cap
pathway
observ
vsv
l
protein
abraham
et
al
b
transfer
gdp
rather
gmp
onto
nascent
transcript
subsequ
l
protein
spring
viremia
carp
viru
gupta
roy
human
respiratori
syncyti
viru
barik
chandipura
viru
ogino
banerje
shown
perform
similar
reaction
presum
follow
rna
cap
pathway
discoveri
add
novel
enzym
process
pathway
involv
uniqu
lencod
gdp
polyribonucleotidyltransferas
activ
prntase
form
coval
enzymeprna
intermedi
involv
phosphoamid
bond
conserv
catalyt
histidin
present
hr
motif
instead
lysin
use
convent
gtase
ogino
banerje
gdp
gener
gtp
ogino
banerje
yetunknown
ntpase
transfer
monophophoryl
viral
mrna
end
coval
attach
prntase
interestingli
methyl
sequenc
also
differ
convent
pathway
sequenc
rna
cap
first
methyl
ribos
posit
first
nucleotid
follow
guanin
posit
gener
rna
structur
crystal
structur
avail
yet
guid
drug
design
uniqu
enzym
prntase
consid
prime
target
perhap
amen
antivir
design
common
mtase
fold
effort
antivir
design
made
rsv
sizeabl
market
exist
interestingli
two
compound
famili
submicromolar
activ
ic
nm
describ
liuzzi
et
al
sudo
et
al
target
l
protein
potent
compound
respect
seri
use
elicit
resist
resist
mutat
map
l
region
domain
consist
presenc
prntase
although
prntase
discov
public
compound
mechanist
studi
clearli
indic
guanylyl
step
actual
target
compound
rsv
two
product
approv
antivir
therapi
prevent
monoclon
antibodi
palivizumab
synagi
ribavirin
empey
et
al
vigant
lee
latter
serv
control
compound
moder
antivir
effect
discoveri
prntase
inhibitor
precis
mechan
action
ribavirin
ie
cap
error
catastroph
imp
dehydrogenas
els
leyssen
et
al
severson
et
al
zhou
et
al
mononegaviral
remain
investig
togavirida
ss
rna
virus
exemplifi
alphavirus
semliki
forest
viru
sindbi
viru
chikungunya
viru
synthes
structur
anoth
nonconvent
mechan
fig
enzym
presum
involv
cap
pathway
poorli
character
crystal
structur
yet
avail
nevertheless
like
cap
begin
methyl
gtp
molecul
mtase
methyl
seemingli
follow
format
coval
gmpenzym
complex
involv
conserv
histidin
catalyt
residu
ahola
et
al
gtp
seem
preced
format
enzymegmp
complex
sinc
guanyl
intermedi
observ
absenc
adomet
ahola
ahola
et
al
wherea
gmp
transfer
onto
end
viral
rna
yet
formal
demonstr
expect
end
viral
rna
bear
diphosph
hydrolysi
bc
phosphat
bond
end
mediat
rtpase
domain
vasiljeva
et
al
brome
mosaic
viru
replicas
protein
ahola
ahlquist
bamboo
mosaic
viru
protein
tobacco
mosaic
viru
merit
et
al
hepat
e
viru
magden
et
al
report
share
properti
alphaviru
mtase
gtase
interestingli
sindbi
viru
semliki
forest
viru
report
year
ago
contain
addit
methyl
group
attach
exocycl
cap
structur
hsuchen
dubin
van
duijn
et
al
role
methyl
viru
replic
still
unknown
reminisc
tmg
cap
found
noncod
eukary
rna
small
nuclear
sn
small
nucleolar
sno
rna
telomeras
rna
busch
et
al
seto
et
al
ribavirin
show
broad
spectrum
vitro
inhibitori
activ
rna
virus
presum
differ
mode
action
leyssen
et
al
severson
et
al
zhou
et
al
case
alphavirus
resist
mutant
ribavirin
map
gtase
domain
protein
scheidel
et
al
scheidel
stollar
suggest
ribavirin
interfer
gtase
activ
nevertheless
ribavirin
action
mode
remain
controversi
ribavirin
also
reduc
intracellular
concentr
gtp
leyssen
et
al
andor
stimul
express
interferonstimul
gene
protein
thoma
et
al
known
sens
viral
rna
devoid
decroli
et
al
et
al
addit
effort
focus
identif
specif
inhibitor
target
specif
cap
activ
sever
gtp
analogu
report
inhibit
semliki
forest
viru
mtase
gtase
activ
k
valu
lm
virusmedi
rna
cap
snatch
cap
snatch
mechan
common
altern
viral
strategi
cap
format
instead
make
rna
cap
viru
machineri
remov
transfer
snatch
cap
host
mrna
onto
premrna
fig
three
major
human
pathogen
famili
arenavirida
bunyavirida
orthomyxovirida
fig
ss
rna
virus
develop
strategi
bouloy
et
al
caton
robertson
plotch
et
al
orthomyxovirida
serv
paradigm
mechanist
structur
studi
case
influenza
viru
replic
complex
made
three
protein
form
polymeras
complex
pa
host
cell
mrna
present
cytoplasm
target
recruit
present
cap
mrna
endonucleas
domain
pa
snip
cap
short
cap
rna
use
primer
polymer
viral
rna
first
structur
endonucleas
domain
potenti
involv
cap
snatch
recent
identifi
arenavirida
bunyavirida
l
protein
morin
et
al
reguera
et
al
endoas
fig
endonucleas
fold
featur
four
mix
bstrand
form
twist
sheet
surround
seven
ahelic
fig
b
sheet
form
bottom
neg
charg
caviti
creat
bind
site
dival
cation
ctermin
helix
posit
patch
creat
anoth
pocket
accommod
rna
typic
conserv
pd
de
xk
nucleas
motif
defin
catalyt
site
fourth
exampl
cap
snatch
recent
describ
totivirida
fungal
viru
fujimura
esteban
howev
case
totiviru
la
transfer
snatch
cellular
mrna
henc
mechan
lie
somewher
alphavirus
transfer
acquir
gtp
convent
capsnatch
virus
describ
transfer
longer
cap
rna
oligonucleotid
addit
similar
alphavirus
totiviru
la
capsnatch
enzym
make
coval
intermedi
histidin
residu
fujimura
esteban
ahola
et
al
ribavirin
effect
inhibitor
arenavirida
olschlag
et
al
bunyavirida
livonesi
et
al
severson
et
al
effect
discuss
thu
direct
evid
rna
cap
snatch
process
actual
target
first
discoveri
inhibitor
cap
snatch
pathway
made
tomassini
et
al
report
acid
compound
abl
inhibit
influenza
b
virus
infect
cell
cultur
tomassini
et
al
remark
compound
exhibit
ic
valu
micromolar
rang
compar
ic
valu
observ
purifi
polymeras
core
use
vitro
endonucleas
assay
follow
chemic
diversif
parent
compound
could
achiev
high
specif
influenza
inde
compound
reach
ic
valu
lm
influenza
vitro
endonucleas
assay
ic
valu
lm
viral
titer
assay
use
influenza
viru
infect
cell
la
cross
viru
bunyavirida
rna
cap
rna
polymeras
prime
reli
also
cap
snatch
remain
unaffect
enzym
viru
level
interestingli
la
cross
viru
replic
cytoplasm
exclus
unlik
influenza
viru
therefor
rna
cap
like
snatch
differ
cellular
compart
environ
two
virus
consider
earli
step
drug
design
larg
spectrum
inhibitor
structur
basi
inhibit
mechan
provid
crystal
structur
la
cross
viru
endonucleas
domain
complex
dpba
reguera
et
al
fig
endoas
inhibitor
structur
homolog
three
avail
crystal
structur
indic
common
pharmacophor
includ
mn
chelat
function
group
might
activ
three
viral
famili
base
crystal
structur
sever
compound
famili
describ
antivir
activ
character
use
enzymebas
assay
viral
growth
assay
protein
structur
data
first
compound
benefit
structurebas
activ
analysi
catechin
isol
green
tea
although
seem
target
neuraminidas
song
et
al
endonucleas
one
activ
pharmacophor
identifi
group
extend
famili
interest
compound
thalidomid
deriv
activ
moieti
later
marchantinlik
phytochem
produc
high
yield
liverwort
iwai
et
al
togeth
enzym
virusinfect
cell
assay
dock
latter
compound
pa
endonucleas
activ
site
gave
interest
perspect
effect
drug
target
influenza
rna
cap
viral
rna
cap
machineri
remark
divers
organ
structur
mechan
use
enzym
rna
virus
cap
viral
rna
evolv
enzym
profoundli
differ
host
cell
power
antivir
compound
screen
design
increas
doubt
viral
rna
cap
enzym
target
novel
highli
effici
select
drug
despit
except
identif
atom
resolut
structur
target
enzym
major
famili
made
signific
progress
last
ten
year
recent
connect
viral
rna
cap
host
cell
innat
immun
mechan
ever
promis
antivir
research
field
